Table 1 Patient demographics and treatment characteristics
Number of patients | 35 |
|---|---|
Median age, years (IQR) | 70 (66.5–74) |
Gleason score (from prostatectomy when available) | |
3 + 3 = 6 | 2 |
3 + 4 = 7 | 8 |
4 + 3 = 7 | 2 |
3 + 5 = 8 | 1 |
4 + 4 = 8 | 5 |
4 + 5 = 9 | 8 |
5 + 4 = 9 | 5 |
5 + 5 = 10 | 4 |
Initial treatment, n (%) | |
Surgery | 17 (48.6) |
Radiation therapy | 8 (22.9) |
Hormonal treatment | 9 (25.7) |
Other | 1 (2.9) |
Type of treatment added after PET1, n (%) | |
ADT | |
Lupron | 4 (11.4) |
Casodex | 4 (11.4) |
Zoladex | 1 (2.9) |
Lupron + Casodex | 3 (8.6) |
ARSi ± ADT | |
Abiraterone | 5 (14.3) |
Enzalutamide | 2 (5.7) |
Apalutamide | 3 (8.6) |
Lupron + Casodex + Darolutamide | 1 (2.9) |
Lupron + Abiraterone | 10 (28.6) |
Lupron + Apalutamide | 1 (2.9) |
Lupron + Enzalutamide | 1 (2.9) |
Castration status at PET1, n (%) | |
Castration-sensitive | 29 (82.9) |
Castration-resistant | 6 (17.1) |
Median Days Under ADT/ARSi (IQR) | 324 (221–550) |
Patients on ADT/ARSi ≤ 90 days, n (%) | 1 (2.9) |
Patients on ADT/ARSi between 90 and 180 days, n (%) | 6 (17.1) |
Patients on ADT/ARSi between 180 and 365 days, n (%) | 15 (42.9) |
Patients on ADT/ARSi ≥ 365 days, n (%) | 13 (37.1) |
Reason for PET2 referral | |
Localization of biochemical recurrence, n (%) | 14 (40) |
Therapy response assessment, n (%) | 3 (8.6) |
Subsequent treatment strategy, n (%) | 4 (11.4) |
Restaging after multiple therapies, n (%) | 12 (34.3) |
Other, n (%) | 2 (5.7) |
Median days between PET1 and PET2 (IQR) | 539 (355.5–802) |
Median days between PET1 and ADT/ARSi initiation (IQR) | 26 (6.5–79.5) |
Median days between ADT/ARSi Initiation and PET2 (IQR) | 380 (248–617.5) |
Median days to PSA progression from ADT/ARSi initiation (IQR) | 1022 (708.5–1348.5) |